Top
image credit: Unsplash

UniQure, with sale of plant, outsources Hemgenix manufacturing

The Lexington plant is a central production hub for UniQure, which describes it as “one of the world’s leading, most versatile, gene therapy manufacturing facilities.” The company has for years pitched it as a competitive advantage in the field, affording it a level of flexibility and control that outsourcing wouldn’t.

But UniQure is in a different position now, having licensed Hemgenix, its only approved treatment, to CSL and facing cost pressures. In October, the company laid off one-fifth of its staff and shuttered a research facility that was also located in Lexington. The gene therapy field has undergone a retrenchment as some of the first therapies to reach market, Hemgenix included, struggle to gain traction.

Read More on Biopharma Dive